The firm said that its HSV and varicella-zoster virus assay delivers answers for related herpes conditions in about an hour.
The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.
The company also reported a jump in its first quarter net loss as operating expenses climbed on higher research and development spending.
The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.
Roche said that the test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting resistance to the antibiotics rifampicin and isoniazid.
The PCR-based test is designed to detect 47 antibiotic resistance genes in less than three hours from bacterial isolates to help guide treatment decisions.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The firm has three clinical trials in progress to validate the clinical utility of products it soon intends to submit for regulatory clearances to the FDA.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
The upgrades include a method to connect Panther systems to create a higher-throughput system that can be configured to different footprints.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes
The moves come in the wake of an FBI search of the company's San Francisco office as part of an investigation into its billing practices.
The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.
The developer of assays to detect drug-resistant strains of HIV has now branched into Lassa detection, and will potentially be seeking instrument partners.
The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.
Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
Based on sequences for hundreds of E. coli ST131 lineage isolates, researchers propose a model that involves negative frequency-dependent selection on accessory parts of the genome.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.